Europe Neisseria meningitidis Infections Drug Market Size, Status and Forecast 2014-2026

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • The Neisseria meningitidis Infections Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.4% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Neisseria meningitidis Infections Drug Market Segmentations:

    By Player:

    • Wellstat Vaccines LLC

    • Biological E Ltd

    • Panacea Biotec Ltd

    • JN-International Medical Corp

    • Serum Institute of India Ltd

    • MGB Biopharma Ltd

    • Griffith University

    • China National Pharmaceutical Group Corp

    • Pfizer Inc

    • Sanofi Pasteur SA

    • ImmunoBiology Ltd

    • GlaxoSmithKline Plc

    • Beijing Minhai Biotechnology Co Ltd

    By Type:

    • MGBBP-3

    • NCL-195

    • TP-10

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Neisseria meningitidis Infections Drug Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of MGBBP-3 from 2014 to 2026

    • 1.3.2 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of NCL-195 from 2014 to 2026

    • 1.3.3 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of TP-10 from 2014 to 2026

    • 1.3.4 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of Clinic from 2014 to 2026

    • 1.4.3 Europe Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Neisseria meningitidis Infections Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Neisseria meningitidis Infections Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of MGBBP-3

      • 3.4.2 Market Size and Growth Rate of NCL-195

      • 3.4.3 Market Size and Growth Rate of TP-10

      • 3.4.4 Market Size and Growth Rate of Others

    4 Segmentation of Neisseria meningitidis Infections Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Neisseria meningitidis Infections Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospital for Construction

      • 4.4.2 Market Size and Growth Rate of Clinic for Construction

      • 4.4.3 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Neisseria meningitidis Infections Drug Production Analysis by Top Regions

    • 5.2 Europe Neisseria meningitidis Infections Drug Consumption Analysis by Top Regions

    • 5.3 Europe Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.3 France Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    6 Product Circulation of Neisseria meningitidis Infections Drug Market among Top Countries

    • 6.1 Top 5 Export Countries in Neisseria meningitidis Infections Drug Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Neisseria meningitidis Infections Drug Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Neisseria meningitidis Infections Drug Landscape Analysis

    • 7.1 Germany Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 7.2 Germany Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    8. UK Neisseria meningitidis Infections Drug Landscape Analysis

    • 8.1 UK Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 8.2 UK Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    9. France Neisseria meningitidis Infections Drug Landscape Analysis

    • 9.1 France Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 9.2 France Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    10. Italy Neisseria meningitidis Infections Drug Landscape Analysis

    • 10.1 Italy Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 10.2 Italy Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    11. Spain Neisseria meningitidis Infections Drug Landscape Analysis

    • 11.1 Spain Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 11.2 Spain Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    12. Poland Neisseria meningitidis Infections Drug Landscape Analysis

    • 12.1 Poland Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 12.2 Poland Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    13. Russia Neisseria meningitidis Infections Drug Landscape Analysis

    • 13.1 Russia Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 13.2 Russia Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    14. Switzerland Neisseria meningitidis Infections Drug Landscape Analysis

    • 14.1 Switzerland Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 14.2 Switzerland Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    15. Turkey Neisseria meningitidis Infections Drug Landscape Analysis

    • 15.1 Turkey Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 15.2 Turkey Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Landscape Analysis by Top Countries

      • 16.3.1 Denmark Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 16.3.2 Finland Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 16.3.3 Norway Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 16.3.4 Sweden Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 16.3.6 Iceland Neisseria meningitidis Infections Drug Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Landscape Analysis by Top Countries

      • 17.3.1 Belgium Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 17.3.2 Netherlands Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 17.3.3 Luxembourg Neisseria meningitidis Infections Drug Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Landscape Analysis by Top Countries

      • 18.3.1 Estonia Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 18.3.2 Latvia Neisseria meningitidis Infections Drug Market Volume and Growth Rate

      • 18.3.3 Lithuania Neisseria meningitidis Infections Drug Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Wellstat Vaccines LLC

      • 19.1.1 Wellstat Vaccines LLC Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Biological E Ltd

      • 19.2.1 Biological E Ltd Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Panacea Biotec Ltd

      • 19.3.1 Panacea Biotec Ltd Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 JN-International Medical Corp

      • 19.4.1 JN-International Medical Corp Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Serum Institute of India Ltd

      • 19.5.1 Serum Institute of India Ltd Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 MGB Biopharma Ltd

      • 19.6.1 MGB Biopharma Ltd Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Griffith University

      • 19.7.1 Griffith University Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 China National Pharmaceutical Group Corp

      • 19.8.1 China National Pharmaceutical Group Corp Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Pfizer Inc

      • 19.9.1 Pfizer Inc Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Sanofi Pasteur SA

      • 19.10.1 Sanofi Pasteur SA Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 ImmunoBiology Ltd

      • 19.11.1 ImmunoBiology Ltd Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 GlaxoSmithKline Plc

      • 19.12.1 GlaxoSmithKline Plc Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Beijing Minhai Biotechnology Co Ltd

      • 19.13.1 Beijing Minhai Biotechnology Co Ltd Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    The List of Tables and Figures (Totals 120 Figures and 172 Tables)

    • Figure Product Picture

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of MGBBP-3 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of NCL-195 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of TP-10 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure UK Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure France Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Neisseria meningitidis Infections Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Neisseria meningitidis Infections Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Neisseria meningitidis Infections Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Neisseria meningitidis Infections Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Neisseria meningitidis Infections Drug by Different Types from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of MGBBP-3 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of NCL-195 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of TP-10 Market, 2015 - 2026 (USD Million)

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Neisseria meningitidis Infections Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Neisseria meningitidis Infections Drug by Different End-Users from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Neisseria meningitidis Infections Drug Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Neisseria meningitidis Infections Drug Production by Major Regions

    • Table Europe Neisseria meningitidis Infections Drug Production Share by Major Regions

    • Figure Europe Neisseria meningitidis Infections Drug Production Share by Major Countries and Regions in 2014

    • Table Europe Neisseria meningitidis Infections Drug Consumption by Major Regions

    • Table Europe Neisseria meningitidis Infections Drug Consumption Share by Major Regions

    • Table Germany Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table UK Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table France Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Italy Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Spain Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Poland Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Russia Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Switzerland Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Turkey Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Neisseria meningitidis Infections Drug Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Germany Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Germany Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Germany Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table UK Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table UK Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table UK Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table UK Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table France Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table France Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table France Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table France Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Italy Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Italy Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Italy Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Italy Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Spain Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Spain Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Spain Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Spain Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Poland Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Poland Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Poland Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Poland Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Russia Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Russia Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Russia Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Russia Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Switzerland Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Switzerland Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Switzerland Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Turkey Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Turkey Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Turkey Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Neisseria meningitidis Infections Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Neisseria meningitidis Infections Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Neisseria meningitidis Infections Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Neisseria meningitidis Infections Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Wellstat Vaccines LLC Profiles

    • Table Wellstat Vaccines LLC Production, Value, Price, Gross Margin 2014-2019

    • Table Wellstat Vaccines LLC Product benchmarking

    • Table Wellstat Vaccines LLC Strategic initiatives

    • Table Wellstat Vaccines LLC SWOT analysis

    • Table Biological E Ltd Profiles

    • Table Biological E Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Biological E Ltd Product benchmarking

    • Table Biological E Ltd Strategic initiatives

    • Table Biological E Ltd SWOT analysis

    • Table Panacea Biotec Ltd Profiles

    • Table Panacea Biotec Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Panacea Biotec Ltd Product benchmarking

    • Table Panacea Biotec Ltd Strategic initiatives

    • Table Panacea Biotec Ltd SWOT analysis

    • Table JN-International Medical Corp Profiles

    • Table JN-International Medical Corp Production, Value, Price, Gross Margin 2014-2019

    • Table JN-International Medical Corp Product benchmarking

    • Table JN-International Medical Corp Strategic initiatives

    • Table JN-International Medical Corp SWOT analysis

    • Table Serum Institute of India Ltd Profiles

    • Table Serum Institute of India Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Serum Institute of India Ltd Product benchmarking

    • Table Serum Institute of India Ltd Strategic initiatives

    • Table Serum Institute of India Ltd SWOT analysis

    • Table MGB Biopharma Ltd Profiles

    • Table MGB Biopharma Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table MGB Biopharma Ltd Product benchmarking

    • Table MGB Biopharma Ltd Strategic initiatives

    • Table MGB Biopharma Ltd SWOT analysis

    • Table Griffith University Profiles

    • Table Griffith University Production, Value, Price, Gross Margin 2014-2019

    • Table Griffith University Product benchmarking

    • Table Griffith University Strategic initiatives

    • Table Griffith University SWOT analysis

    • Table China National Pharmaceutical Group Corp Profiles

    • Table China National Pharmaceutical Group Corp Production, Value, Price, Gross Margin 2014-2019

    • Table China National Pharmaceutical Group Corp Product benchmarking

    • Table China National Pharmaceutical Group Corp Strategic initiatives

    • Table China National Pharmaceutical Group Corp SWOT analysis

    • Table Pfizer Inc Profiles

    • Table Pfizer Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Inc Product benchmarking

    • Table Pfizer Inc Strategic initiatives

    • Table Pfizer Inc SWOT analysis

    • Table Sanofi Pasteur SA Profiles

    • Table Sanofi Pasteur SA Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi Pasteur SA Product benchmarking

    • Table Sanofi Pasteur SA Strategic initiatives

    • Table Sanofi Pasteur SA SWOT analysis

    • Table ImmunoBiology Ltd Profiles

    • Table ImmunoBiology Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table ImmunoBiology Ltd Product benchmarking

    • Table ImmunoBiology Ltd Strategic initiatives

    • Table ImmunoBiology Ltd SWOT analysis

    • Table GlaxoSmithKline Plc Profiles

    • Table GlaxoSmithKline Plc Production, Value, Price, Gross Margin 2014-2019

    • Table GlaxoSmithKline Plc Product benchmarking

    • Table GlaxoSmithKline Plc Strategic initiatives

    • Table GlaxoSmithKline Plc SWOT analysis

    • Table Beijing Minhai Biotechnology Co Ltd Profiles

    • Table Beijing Minhai Biotechnology Co Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Beijing Minhai Biotechnology Co Ltd Product benchmarking

    • Table Beijing Minhai Biotechnology Co Ltd Strategic initiatives

    • Table Beijing Minhai Biotechnology Co Ltd SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.